Ticker PFE

Today's data summary

Market closed
% change
Price US dollars
As of 09:53 21 Aug 2019
Market cap. US dollars
202,887.61 million
As of 09:53 21 Aug 2019

Latest updates

Tie-up between makers of EpiPens and Viagra

Getty Images

A pharmaceutical deal has been announced which would unite EpiPen and Viagra.

Mylan, the maker of EpiPens, and the Upjohn unit of Pfizer, which makes Viagra, are being united in an all-share deal.

Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%, Mylan said.

Each Mylan share would be converted into one share of the new company.

GSK deal: 'some impact on people'

GSK logo
Getty Images

GlaxoSmithKline's shares are still up 7% following the tie-up announced with Pfizer.

The company has said that the deal will save costs and this looks likely to have an impact on staff.

Emma Walmsley, chief executive of Glaxo, said: "Obviously there's going to be some impact on people. That's something we are working through and we will certainly be talking to our employees before we start talking about that in any way publicly."

GSK: Pressure on white coats

More on the plans announced earlier by GlaxoSmithKline to link its consumer health business with Pfizer and spin it off in three years.

The separation will take away the steady cash flows of the consumer business, meaning there’s more pressure on the men and women in white coats to deliver the next generation of blockbusters. However, the potential to shift significant amounts of debt onto the cash generative consumer business should take the strain off the balance sheet, and thus buy valuable time for the pipeline to deliver. There’s also the fact that as a specialist pharma group, investors can be more confident GSK can get better results from the labs.

George SalmonEquity Analyst, Hargreaves Lansdown

'Deaf ears'

gsk logo
Getty Images

GlaxoSmithKline has faced calls from investors in the past to spin off the consumer healthcare division, George Salmon, analyst at Hargreaves Lansdown explains.

The previous chief executive, Sir Andrew Witty, did not respond to the calls.

So today's announcement to spin off the division is a "surprise".

"Under Andrew Witty’s leadership, calls for GSK to spin off the consumer healthcare businesses fell on deaf ears, and until now it looked like new CEO Emma Walmsley would follow suit and ignore claims that GSK’s parts are worth more than the whole".

GSK + Pfizer

pictures of all the brands

It's a landmark day for GlaxoSmithKline, says its chief executive Emma Walmsley.

She is speaking to analysts after announcing a tie-up with Pfizer and plans to spin off the consumer heath care unit in three years.

She has been telling them about the unification of "category leading power brands" (shown above).

GSK's shares price are up 7%.

GSK divi promise

Centrum bottles

GSK has told its shareholders that it intends to pay an unchanged dividend of 80p per share for 2019.

This is an attempt to show shareholders that its financial position will not be weakened by the deal with Pfizer's consumer health care division.

Its shareholders must vote through the deal which includes Pfizer products such as Advil painkillers and Centrum vitamins.

$900m break-fee

Emma Walmsley

GSK will pay a break fee of $900m if the company changes its mind about the Pfizer deal or if the shareholders do not approve it by 30 September 2019.

Emma Walmsley, GSK's chief executive, said: "Through the combination of GSK and Pfizer's consumer healthcare businesses we will create substantial further value for shareholders".

GSK spin off


More on the GSK/Pfizer deal.

Within three years of the closing of the transaction, GSK intends to list GSK Consumer Healthcare on the stock market.

Earlier this year, there were reports that the company was under pressure from investors to hive off this arm which owns products such as Panadol and Aquafresh.